OSLO--(BUSINESS WIRE)-- The Norwegian pharmaceutical company Lytix Biopharma AS provided an update at the recent BIO conference in Chicago on Phase I clinical trials of OncoporeTM (LTX-315) for the treatment of cancer.
During a session hosted by the European Cancer Cluster (Norwegian Oslo Cancer Cluster and French Cancer-Bio-Santé Cluster) at the recent BIO conference in Chicago, Head of Lytix Biopharma Business Development Anders Fugelli, PhD provided an update on the Phase I study of OncoporeTM (LTX-315) for the treatment of solid tumours. The study is set up to include patients at two main centres, The Norwegian Radium Hospital – National Hospital in Oslo, and the Karolinska University Hospital in Stockholm, Sweden, and will initially establish a safe and tolerated dose of LTX-315 when given to solid tumours amenable to injection. The study received regulatory and ethical approvals at the end of last year and is currently actively including patients. Up to 40 patients with transdermally accessible solid tumours will be included. The study will investigate the primary tumour necrotic event after local injection as well as the subsequent triggering of an anti-tumour immune response such as observed in animal models. The treatment of tumours by injection of OncoporeTM as an ‘in situ vaccination’ holds the potential to become a valuable new therapy for a variety of solid tumours.
Lytix Biopharma AS intends to develop OncoporeTM to a clinical Proof-of-Concept stage whilst seeking pharma/biotech partners to support later-stage clinical development and commercialisation.
About Lytix Biopharma AS
Lytix Biopharma AS develops novel drugs for the treatment of resistant bacterial and fungal infections, as well as first-in-class oncology treatments. The Company was established in 2003 to commercialise world-class research in the field of lytic peptides spun out by the founding scientists working at the University of Tromsø and University Hospital in Norway. Operating out of Tromsø and Oslo and through a continued collaboration with the University of Tromsø the Company has access to state-of-the-art laboratories and staff with extensive experience of drug discovery research. Business and product development is driven from the subsidiary office in Oslo.
Gunnar Sælid, CEO
Tel +47 911 92 330
Anders Fugelli, Director, Business Development
Tel +47 924 81 432
Richard Hayhurst, Schwartz Communications
Tel +44 (0) 7950 878218 Email: [email protected]
KEYWORDS: United States Europe North America Norway Illinois
INDUSTRY KEYWORDS: Health Biotechnology Oncology Pharmaceutical